Successful lanadelumab dose spacing in type I hereditary angioedema

Type I hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent bradykinin-mediated angioedema affecting the skin, respiratory, and gastrointestinal tracts. Lanadelumab, a monoclonal antibody targeting plasma kallikrein to reduce bradykinin production, has shown efficacy in long-term prophylaxis (LTP) for patients aged 2 and above, with a recommended dose of 300 mg biweekly. We present two cases of type I HAE patients, poorly controlled with traditional LTP therapies, demonstrating complete response and extended attack-free intervals with lanadelumab, suggesting that administration intervals beyond 4 weeks may be feasible, improving patient quality of life and healthcare cost-effectiveness.